{"id":"biib091","safety":{"commonSideEffects":[{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL5083772","moleculeType":"Small molecule","molecularWeight":"542.65"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CD47 is a protein that can interfere with the body's ability to recognize and destroy cancer cells. By targeting CD47, BIIB091 aims to enhance the body's immune response against cancer.","oneSentence":"BIIB091 is a monoclonal antibody targeting CD47.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:54.077Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT05798520","phase":"PHASE2","title":"A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2023-07-25","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":127},{"nctId":"NCT06574828","phase":"PHASE1","title":"A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2024-08-29","conditions":"Healthy Volunteer","enrollment":69},{"nctId":"NCT06640933","phase":"PHASE1","title":"A Study to Find Out How Different Forms of BIIB091 is Processed in The Body With and Without Food in Healthy Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2024-10-16","conditions":"Healthy Volunteer","enrollment":25},{"nctId":"NCT06311786","phase":"PHASE1","title":"A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2024-04-08","conditions":"Healthy Volunteer","enrollment":8},{"nctId":"NCT04564612","phase":"PHASE1","title":"Study of BIIB091 Formulations in Healthy Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2020-09-28","conditions":"Healthy Volunteers","enrollment":59},{"nctId":"NCT03943056","phase":"PHASE1","title":"A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2019-05-13","conditions":"Healthy Volunteer","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BIIB091","genericName":"BIIB091","companyName":"Biogen","companyId":"biogen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BIIB091 is a monoclonal antibody targeting CD47. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}